Galena Biopharma (GALE) Initiates RELIEF Patient Registry for Abstral®, Launches Sales Campaign

Galena Biopharma, a Portland -based biopharmaceutical company focused on developing innovative, targeted oncology treatments to advance cancer care, this morning reports the initiation of its registry study entitled RELIEF: Rapid Evaluation of Lifestyle, Independence, and Elimination of breakthrough cancer pain with Freedom from oral discomfort through the use of Abstral® (fentanyl) Sublingual Tablets.

The Institutional Review Board (IRB)-approved cancer patient registry study is a post-marketing multicenter trial to assess Abstral for breakthrough cancer pain (BTcP) in opioid-tolerant cancer patients. Abstral is currently available to patients and health care professionals at pharmacies nationwide.

GALE has begun recruitment and enrollment of approximately 2,500 patients. RELIEF is expected to be completed by enrolled patients over a 30-day period while using Abstral for treatment of their breakthrough cancer pain.

“With collaboration and support from the physician community, we are excited to initiate our RELIEF trial and debut Abstral this week, which we believe is the best product in this class of drugs for patients suffering from breakthrough cancer pain,” Mark J. Ahn, GALE’s president and CEO stated in the press release. “Abstral’s product features, including its ease of use, and lack of product disposal issues, make it an important treatment option for these patients,” he said. “The RELIEF registry is a critical initiative that will help assess the attributes of the drug and provide a sizeable data set to support physicians who prescribe Abstral.”

GALE also said it has kicked-off Abstral’s sales and marketing campaign at PAINWeek, one of the nation’s largest pain conferences, held in Las Vegas, NV, September 4-7, 2013. GALE has fully staffed its commercial team in preparation for a fourth-quarter launch, backed by senior level executives and a highly experienced sales force.

“The initiation of our registry program ahead of our official launch is an important first step in our overall commercial plan as the second half of the year will be transformational for Galena, as we generate sales and become a revenue producing organization,” concluded Ahn.

For more information, visit www.galenabiopharma.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html